Research Use Only Notice: This article is about GHRP-6 as a laboratory research peptide. The information below applies only to in-vitro studies, ex-vivo work, and approved laboratory animal models handled by trained researchers.
GHRP-6 is not FDA-approved for human use, personal use, veterinary use, diagnosis, treatment, or any clinical application. Numerical dose-response values are reported only when necessary to accurately summarize published laboratory animal studies; this article does not provide practical reconstitution, administration, or treatment instructions.
GHRP-6 is a synthetic six-residue growth hormone secretagogue that was initially investigated for its ability to stimulate pituitary growth hormone release and was subsequently used as a laboratory research tool. A 1984 study reported that GHRP-6 increased growth hormone release in isolated pituitary preparations and in several laboratory animal models.[1]

Later research showed that GHRP-6 acts primarily through the functional growth hormone secretagogue receptor isoform GHS-R1a, commonly called the ghrelin receptor. This receptor was cloned in 1996, and ghrelin was identified as an endogenous ligand in 1999.[2][3]
Molecular Identity
| Item | GHRP-6 Data |
|---|---|
| Sequence | His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ |
| Length | 6 amino-acid residues |
| Molecular formula | C₄₆H₅₆N₁₂O₆ |
| Average molecular weight | 873.0 g/mol |
| Monoisotopic neutral mass | 872.4446 Da |
| Theoretical [M+H]⁺ | m/z 873.4519 |
| Theoretical [M+2H]²⁺ | m/z 437.2296 |
| CAS Registry Number | 87616-84-0 |
| PubChem CID | 9919153 |
| C-terminus | Amidated |
The sequence, formula, average molecular weight, monoisotopic mass, CAS number, and stereochemically defined PubChem entry above match the GHRP-6 structure His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂. The monoisotopic neutral mass of 872.4446 Da and theoretical charge-state ions are calculated from C₄₆H₅₆N₁₂O₆.[4]
The listed molecular weight is for the free peptide. A supplied research lot may also contain an acetate, trifluoroacetate, or another counter-ion, as well as water left from processing.
For accurate concentration work, researchers should use the salt form, water result, and net peptide content shown on the lot-specific certificate of analysis.
How GHRP-6 Works in Laboratory Studies
In receptor-based laboratory systems, GHS-R1a is mainly linked to the Gq/11 pathway. Receptor activation can turn on phospholipase C, increase inositol trisphosphate and diacylglycerol, and raise calcium inside the cell.[5]
In rat primary pituitary cell culture, GHRP-6 increased growth hormone release in a time- and concentration-dependent way, with an approximate half-maximal effective concentration (EC50) of 7 × 10−9 M and a maximal response at about 10−7 M. In that study, GHRP-6 alone did not raise intracellular cAMP, while growth hormone-releasing hormone (GHRH; termed growth hormone-releasing factor, GRF, in the cited historical study) did.
When the two signals were added together, the growth hormone response was greater than with either signal alone, and GHRP-6 enhanced the GHRH-induced cAMP elevation.[6]
These results show that GHRP-6 and GHRH can act through different signaling routes in the same laboratory system. They do not support any human or veterinary combination-use instruction.
Findings in Laboratory Animal Models
Raun and colleagues compared GHRP-6, GHRP-2, and ipamorelin in conscious swine. In that study, GHRP-6 had a growth hormone ED50 of 3.9 ± 1.4 nmol/kg and an estimated maximum response of 74 ± 7 ng/mL.
These numbers apply only to the study design, species, route, and sampling method used in that paper.[7]
In the same swine study, GHRP-6 and GHRP-2 increased ACTH and cortisol. Ipamorelin did not cause a significant ACTH or cortisol increase under the tested conditions, even at doses far above its growth hormone ED50.
None of the three peptides significantly changed FSH, LH, prolactin, or TSH in that experiment.[7]
Rat studies also found that GHRP-6 activated cells in the hypothalamic arcuate nucleus. One study reported increased Fos and Egr-1 signals, with a larger response in fasted rats than in fed rats.[8]
Another study found that approximately 51% of GHRP-6-activated arcuate cells expressed neuropeptide Y mRNA and about 23% expressed GHRH (GRF) mRNA.[9]
In a separate rat experiment, a neuropeptide-Y Y1 receptor antagonist blocked the feeding response caused by centrally administered GHRP-6.[10] This supports a role for an NPY-related pathway in that animal model.
It does not prove that one specific amino acid in GHRP-6 is solely responsible for the effect.
Comparison with GHRP-2 and Ipamorelin
| Feature | GHRP-6 | GHRP-2 | Ipamorelin |
|---|---|---|---|
| Sequence | His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ | D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH₂ | Aib-His-D-2Nal-D-Phe-Lys-NH₂ |
| Length | 6 residues | 6 residues | 5 residues |
| Average MW | 873.0 g/mol | 818.0 g/mol[11] | 711.9 g/mol[12] |
| Result in the cited swine study | Lower GH potency than GHRP-2, but a higher estimated maximum GH response | Higher GH potency than GHRP-6, but a lower estimated maximum GH response | GH release with less ACTH and cortisol activity under the tested conditions |
The GHRP-2 and ipamorelin sequences in the table match their PubChem entries: GHRP-2 (CAS 158861-67-7, monoisotopic mass 817.4275 Da) and ipamorelin (CAS 170851-70-4, monoisotopic mass 711.3857 Da).[11][12] The swine comparison comes from the Raun study and should not be treated as a universal ranking for all species or laboratory methods.[7]
The three peptides differ at several positions and are not separated only by their number of tryptophan residues. It would therefore be inaccurate to claim that tryptophan count alone explains their hormone-response differences.
Common Research Uses
- Receptor studies: GHRP-6 can be used as a reference agonist in GHS-R1a binding and signaling assays.
- Pituitary cell studies: It can be used to study growth hormone release in validated cell or tissue preparations.
- Signal interaction studies: It can be compared with GHRH to study how two signaling routes affect the same growth hormone endpoint.
- Animal-model neurobiology: It can be used in approved rodent studies of arcuate-nucleus, NPY, and feeding-related pathways.
- Peptide comparison studies: It can serve as a reference when comparing GHRP-2, ipamorelin, or other GHS-R1a ligands under matched test conditions.
Any conclusion should name the exact model, species, assay, dose range, route, and sampling time. Results from cells, rats, or swine must not be presented as proof of an effect in people or as a guide for veterinary treatment.
Storage and Laboratory Solution Handling
Dry GHRP-6 should be stored according to the lot-specific certificate of analysis and available stability data. When no validated condition is supplied, frozen storage, commonly around −20°C, with protection from light and moisture may be used as a provisional laboratory condition rather than a validated shelf-life claim.
The vial should remain sealed during temperature adjustment when condensation is a concern.
Once a peptide is in solution, stability can change with pH, temperature, oxygen, light, salt level, concentration, and the container surface. Peptide solutions may undergo oxidation, hydrolysis, aggregation, precipitation, or surface loss.[13]
GHRP-6 contains two tryptophan residues, so oxidation is one possible stability risk. Identified tryptophan oxidation products in peptides include oxindolylalanine (Oia), 3a-hydroxy-hexahydropyrroloindole-2-carboxylic acid (PIC), N-formylkynurenine (NFK), dioxindolylalanine (DiOia), kynurenine (Kyn), and 5-hydroxytryptophan (5-OH-Trp), reflecting susceptibility of the pyrrole moiety.
These oxidation products should be checked with a suitable method such as RP-HPLC with UV, fluorescence, or photodiode array detection rather than guessed from HPLC peak position alone.[14]
There is no single solvent, pH, concentration, freeze-thaw limit, or solution shelf life that is correct for every GHRP-6 lot and every assay. These conditions should be tested for the actual laboratory method.
Preparing small, single-use aliquots can reduce repeated freeze-thaw exposure, but the acceptable storage period still needs experimental support.
Laboratory use only: This section is not a reconstitution, injection, dosing, or administration guide for humans or animals.
How to Read a GHRP-6 COA
A certificate of analysis describes the tested quality of one batch. It does not prove that the material is safe for human use, suitable for veterinary use, sterile, free of endotoxin, or effective for any clinical purpose.
- HPLC purity: A statement such as “≥98% by HPLC” usually refers to chromatographic area purity under the stated method. It does not automatically equal net peptide content.
- Mass spectrometry: MS or LC-MS can support identity by comparing the observed charge-state ions with values calculated from the monoisotopic neutral mass. The average molecular weight of 873.0 g/mol should not be used as the exact monoisotopic mass for high-resolution MS interpretation. The COA should state whether reported mass values use the average or monoisotopic convention, along with the observed charge states and/or deconvolution method.
- Water: Water content is a separate result and can affect the amount of actual peptide in a weighed sample.
- Counter-ion: Acetate, trifluoroacetate, or another counter-ion can change the mass basis used for concentration calculations.
- Residual solvents: These require their own test and cannot be calculated from HPLC purity.
- Related substances: Oxidized, shortened, deletion-sequence, and other process-related forms may need a method that can separate them from the main peptide.
ICH Q2(R2) states that an analytical method should be suitable for its intended purpose. Depending on the test, this may require evidence for specificity, accuracy, precision, reportable range, and the ability to separate or detect relevant impurities and degradation products.[15]
HPLC and MS answer different questions. HPLC mainly shows how much of the detected chromatographic area belongs to the main peak under one method.
MS helps check molecular identity. A sound COA may use both, along with water, counter-ion, residual-solvent, and other tests that are relevant to the batch.
Research References
- Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545. PubMed PMID 6714155.
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. PubMed PMID 8688086.
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. PubMed PMID 10604470.
- National Center for Biotechnology Information. PubChem Compound Summary for CID 9919153, Growth Hormone Releasing Hexapeptide. PubChem.
- Mear Y, Enjalbert A, Thirion S. GHS-R1a constitutive activity and its physiological relevance. Front Neurosci. 2013;7:87. PubMed Central PMC3665924.
- Cheng K, Chan WW, Barreto A Jr, Convey EM, Smith RG. The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ on growth hormone (GH)-releasing factor-stimulated GH release and intracellular cyclic adenosine 3′,5′-monophosphate accumulation in rat primary pituitary cell culture. Endocrinology. 1989;124(6):2791-2798. PubMed PMID 2541999.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed PMID 9849822.
- Hewson AK, Dickson SL. Systemic administration of ghrelin induces Fos and Egr-1 proteins in the hypothalamic arcuate nucleus of fasted and fed rats. J Neuroendocrinol. 2000;12(11):1047-1049. PubMed PMID 11069119.
- Dickson SL, Luckman SM. Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6. Endocrinology. 1997;138(2):771-777. PubMed PMID 9003014.
- Lawrence CB, Snape AC, Baudoin FM, Luckman SM. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology. 2002;143(1):155-162. PubMed PMID 11751604.
- National Center for Biotechnology Information. PubChem Compound Summary for Pralmorelin (GHRP-2), CID 6918245. PubChem.
- National Center for Biotechnology Information. PubChem Compound Summary for Ipamorelin, CID 9831659. PubChem.
- Nugrahadi PP, Hinrichs WLJ, Frijlink HW, Schöneich C, Avanti C. Designing formulation strategies for enhanced stability of therapeutic peptides in aqueous solutions: a review. Pharmaceutics. 2023;15(3):935. PubMed Central PMC10056213.
- Simat TJ, Steinhart H. Oxidation of free tryptophan and tryptophan residues in peptides and proteins. J Agric Food Chem. 1998;46(2):490-498. doi:10.1021/jf970818c. PubMed PMID 10554268.
- International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. Official ICH guideline.
Research Use Only Disclaimer
Research Use Only: The GHRP-6 material described on this page is supplied for laboratory research purposes only and not FDA-approved for human use. This article provides general scientific information regarding standard laboratory research contexts only, and does not constitute a validated experimental protocol, medical guidance, clinical guidance, veterinary guidance, or treatment advice.